Comparison of Efficacy of Single Dose Tranexamic Acid versus Placebo before Surgery in Females Undergoing Surgery for Ovarian Cancer
DOI:
https://doi.org/10.70749/ijbr.v3i7.2326Keywords:
Comparison of Efficacy, Tranexamic Acid, Placebo, Surgery in Females, Ovarian CancerAbstract
Objective: To compare the efficacy of single-dose tranexamic acid versus placebo in reducing transfusion requirements and perioperative blood loss in females undergoing surgery for ovarian cancer. Methods: This randomized controlled trial was conducted in the Department of Obstetrics and Gynecology, Sheikh Zayed Hospital and Medical College, Rahim Yar Khan, over a 6-month period (December 2024 to May 2025). A total of 372 women aged 18–60 years with ovarian cancer of FIGO stage I–III and ASA class I–III were enrolled and randomized into two groups. Group A (n=186) received tranexamic acid 15 mg/kg intravenously before surgery, while Group B (n=186) received placebo. The primary outcome was efficacy, defined as no postoperative transfusion requirement. Results: All 372 patients completed the study. Baseline characteristics were comparable between groups (p >0.05). The requirement for transfusion was significantly lower in the tranexamic acid group (29.6%) compared to placebo (44.1%) (p=0.003). Efficacy was achieved in 70.4% of patients in the tranexamic acid group versus 55.9% in the placebo group (p=0.003). Mean perioperative blood loss was markedly reduced in the tranexamic acid group (548.3 ± 198.7 ml) compared to placebo (692.1 ± 242.6 ml) (p<0.001). Postoperative hemoglobin levels were significantly higher in the tranexamic acid group (10.2 ± 1.4 g/dl) compared to placebo (9.6 ± 1.6 g/dl) (p=0.001), with a smaller mean hemoglobin decline (1.6 ± 0.8 g/dl vs. 2.3 ± 1.2 g/dl, p<0.001). Conclusion: Single-dose tranexamic acid administered preoperatively significantly reduced transfusion requirements, perioperative blood loss, and hemoglobin decline in ovarian cancer surgery, supporting its use as an effective adjunct in perioperative management.
Downloads
References
1. Johnstone C, Rich SE. Bleeding in cancer patients and its treatment: a review. Ann Palliat Med. 2018;7(2):265–73.
https://doi.org/10.21037/apm.2017.11.01
2. Kim HJ, Moon SH, Cho SH, Lee JD, Kim HS. Efficacy and safety of tranexamic acid in melasma: a meta-analysis and systematic review. Acta Derm Venereol. 2017;97(7):776–81.
https://doi.org/10.2340/00015555-2668
3. Abeysiri S, Chau M, Richards T. Perioperative anemia management. Semin Thromb Hemost. 2020;46(1):8-16.
https://doi.org/10.1055/s-0039-1697933
4. Ramsey G, Lindholm PF. Thrombosis risk in cancer patients receiving red blood cell transfusions. Semin Thromb Hemost. 2019;45(6):648-56.
https://doi.org/10.1055/s-0039-1694763
5. Zec T, Di Napoli R, Fievez L, Ben Aziz M, Ottaiano A, Vittori A, et al. Efficacy and safety of tranexamic acid in cancer surgery. An update of clinical findings and ongoing research. J Multidiscip Healthc. 2022;15:1427-44.
https://doi.org/10.2147/jmdh.s337250
6. Cai J, Ribkoff J, Olson S, et al. The many roles of tranexamic acid: an overview of the clinical indications for TXA in medical and surgical patients. Eur J Haematol. 2020;104(2):79-87.
https://doi.org/10.1111/ejh.13348
7. Tayyba A, Anjum S, Farooq M, Nadeem N, Farooq M, Sohail H, et al. Role of tranexamic acid in reducing blood loss during and after caesarean section. Pak J Med Health Sci. 2020;14(3):558-61.
8. Kietpeerakool C, Supoken A, Laopaiboon M, Lumbiganon P. Effectiveness of tranexamic acid in reducing blood loss during cytoreductive surgery for advanced ovarian cancer. Cochrane Database Syst Rev. 2016;2016(1):CD011732.
https://doi.org/10.1002/14651858.cd011732
9. Sampaio AM, Guimarães GMN, Medeiros GP, Damasceno GMM, Silva RMA, Nunes RR, et al. Eficácia e segurança de antifibrinolíticos em cirurgia oncológica: uma revisão sistemática e metanálise [Efficacy and safety of antifibrinolytics in oncological surgery: a systematic review and meta-analysis]. Braz J Anesthesiol. 2019;69(5):484-92.
https://doi.org/10.1016/j.bjan.2019.06.005
10. Lundin ES, Johansson T, Zachrisson H, Leandersson U, Bäckman F, Falknäs L, et al. Single-dose tranexamic acid in advanced ovarian cancer surgery reduces blood loss and transfusions: double-blind placebo-controlled randomized multicenter study. Acta Obstet Gynecol Scand. 2014;93(4):335-44.
https://doi.org/10.1111/aogs.12333
11. Henry DA, Carless PA, Moxey AJ, O’Connell D, McClelland B, Henderson KM, et al. Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion. Cochrane Database Syst Rev. 2011;(1):CD001886.
https://doi.org/10.1002/14651858.cd001886
12. Ker K, Edwards P, Perel P, Shakur H, Roberts I. Effect of tranexamic acid on surgical bleeding: systematic review and cumulative meta-analysis. BMJ. 2012;344:e3054.
https://doi.org/10.1136/bmj.e3054
13. Roy P, Sujatha VV, Kumar P. Tranexamic acid in reducing blood loss during and after elective caesarean section and abdominal hysterectomy. J Clin Diagn Res. 2017;11(11):QC01-QC04.
14. Sethna F, Joshi S, Bhat R, Thomas A. Efficacy of tranexamic acid in reducing blood loss during myomectomy: a randomized controlled trial. Int J Gynaecol Obstet. 2019;145(3):345-350.
15. Riaz RM, Habib S, Haider G. Role of tranexamic acid in reducing blood loss in abdominal hysterectomy. J Ayub Med Coll Abbottabad. 2019;31(2):213-217.
16. Akbari A, Sadeghi M, Dehghan M. Tranexamic acid in gastrointestinal cancer surgery: impact on blood loss and transfusion requirement. World J Surg Oncol. 2017;15(1):94.
17. Goel R, Patel EU, Cushing MM, Frank SM, Ness PM, Takemoto CM, et al. Association of perioperative red blood cell transfusions with venous thromboembolism in surgical patients. JAMA Surg. 2018;153(9):826-833.
https://doi.org/10.1001/jamasurg.2018.1565
18. Amato A, Pescatori M. Perioperative blood transfusions for the recurrence of colorectal cancer. Cochrane Database Syst Rev. 2006;(1):CD005033.
https://doi.org/10.1002/14651858.cd005033.pub2
19. Fillingham YA, Ramkumar DB, Jevsevar DS, Yates AJ, Shores P, Mullen K, et al. Tranexamic acid in total joint arthroplasty: the clinical practice guidelines. J Arthroplasty. 2018;33(10):3065-3069.
https://doi.org/10.1016/j.arth.2018.03.031
20. Myles PS, Smith JA, Forbes A, Silbert B, Jayarajah M, Painter T, et al. Tranexamic acid in patients undergoing coronary-artery surgery. N Engl J Med. 2017;376(2):136-148.
https://doi.org/10.1056/nejmoa1606424
21. Shimizu T, Takenaka K, Ogawa E, Katoh T, Aoki T, Toyoda A, et al. Efficacy of tranexamic acid for reducing blood loss during hepatic resection: a randomized clinical trial. Br J Surg. 2019;106(12):1588-1596.
22. Wu HL, Tai YH, Lin SP, Chan MY, Chen HH, Chen YJ. Effect of tranexamic acid on blood loss in patients undergoing gastrointestinal cancer surgery: systematic review and meta-analysis. Br J Anaesth. 2015;114(5):781-790.
23. Kagoma YK, Crowther MA, Douketis J, Bhandari M, Eikelboom J, Lim W. Use of antifibrinolytic therapy to reduce transfusion in patients undergoing orthopedic surgery: a systematic review of randomized trials. Thromb Res. 2009;123(5):687-696.
https://doi.org/10.1016/j.thromres.2008.09.015
24. WOMAN Trial Collaborators. Effect of early tranexamic acid administration on mortality, hysterectomy, and other morbidities in women with post-partum haemorrhage (WOMAN): an international, randomized, double-blind, placebo-controlled trial. Lancet. 2017;389(10084):2105-2116.
https://doi.org/10.1097/01.ogx.0000524474.98785.13
25. Fergusson DA, Hébert PC, Mazer CD, Fremes S, MacAdams C, Murkin JM, et al. A comparison of aprotinin and lysine analogues in high-risk cardiac surgery. N Engl J Med. 2008;358(22):2319-2331.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Indus Journal of Bioscience Research
This work is licensed under a Creative Commons Attribution 4.0 International License.
